ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
type: Dataset
description: International audience
landing page: 1942-0862
keyword: bevacizumab
keyword: epistaxis
keyword: hereditary-hemorrhagic-telangiectasia
keyword: infoeu-reposemanticsarticle
keyword: journal-articles
keyword: monoclonal-antibody
keyword: nasal-spray
keyword: phase-1-clinical-study
keyword: sdvlife-sciences-q-bio
keyword: sdvsppharmalife-sciences-q-biopharmaceutical-sciencespharmacology
issued: 2026-05-05T11:14:35.395471
modified: 2026-05-05T11:14:35.395476
language: en
contact point: Organization
  fn: CCSD

test_moissonnage_selune
type: Agent

ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
type: Distribution
format: HTML
access URL: https://univ-tours.hal.science/hal-00991138
issued: 2026-05-05T11:14:35.403145
modified: 2026-05-05T11:14:35.381019